Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial

This study assessed the efficacy and safety of ribavirin‐free coformulated glecaprevir/pibrentasvir (G/P) in patients with hepatitis C virus genotype 3 infection with prior treatment experience and/or compensated cirrhosis, a patient population with limited treatment options. SURVEYOR‐II, Part 3 was...

Descripción completa

Detalles Bibliográficos
Autores principales: Wyles, David, Poordad, Fred, Wang, Stanley, Alric, Laurent, Felizarta, Franco, Kwo, Paul Y., Maliakkal, Benedict, Agarwal, Kosh, Hassanein, Tarek, Weilert, Frank, Lee, Samuel S., Kort, Jens, Lovell, Sandra S., Liu, Ran, Lin, Chih‐Wei, Pilot‐Matias, Tami, Krishnan, Preethi, Mensa, Federico J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817409/
https://www.ncbi.nlm.nih.gov/pubmed/28926120
http://dx.doi.org/10.1002/hep.29541

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817409/
https://www.ncbi.nlm.nih.gov/pubmed/28926120
http://dx.doi.org/10.1002/hep.29541

Ejemplares similares